196 related articles for article (PubMed ID: 8070928)
1. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis.
Beyer J; Schwartz S; Barzen G; Risse G; Dullenkopf K; Weyer C; Siegert W
Infection; 1994; 22(2):143-8. PubMed ID: 8070928
[TBL] [Abstract][Full Text] [Related]
2. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis.
Beyer J; Barzen G; Risse G; Weyer C; Miksits K; Dullenkopf K; Huhn D; Siegert W
Antimicrob Agents Chemother; 1993 Jun; 37(6):1367-9. PubMed ID: 8328788
[TBL] [Abstract][Full Text] [Related]
3. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.
Roth C; Gebhart J; Just-Nübling G; von Eisenhart-Rothe B; Beinhauer-Reeb I
Infection; 1996; 24(5):354-60. PubMed ID: 8923045
[TBL] [Abstract][Full Text] [Related]
4. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients.
Behre GF; Schwartz S; Lenz K; Ludwig WD; Wandt H; Schilling E; Heinemann V; Link H; Trittin A; Boenisch O
Ann Hematol; 1995 Dec; 71(6):287-91. PubMed ID: 8534760
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats.
Ruijgrok EJ; Vulto AG; Van Etten EW
J Antimicrob Chemother; 2001 Jul; 48(1):89-95. PubMed ID: 11418516
[TBL] [Abstract][Full Text] [Related]
6. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
8. Deposition of amphotericin B aerosols in pulmonary aspergilloma.
Diot P; Rivoire B; Le Pape A; Lemarie E; Dire D; Furet Y; Breteau M; Smaldone GC
Eur Respir J; 1995 Aug; 8(8):1263-8. PubMed ID: 7489788
[TBL] [Abstract][Full Text] [Related]
9. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
10. Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin.
Rodenhuis S; Beaumont F; Kauffman HF; Sluiter HJ
Thorax; 1984 Jan; 39(1):78-9. PubMed ID: 6695357
[No Abstract] [Full Text] [Related]
11. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.
Schmitt HJ; Bernard EM; Häuser M; Armstrong D
Antimicrob Agents Chemother; 1988 Nov; 32(11):1676-9. PubMed ID: 3252750
[TBL] [Abstract][Full Text] [Related]
12. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters.
Oren I; Haddad N; Finkelstein R; Rowe JM
Am J Hematol; 2001 Apr; 66(4):257-62. PubMed ID: 11279636
[TBL] [Abstract][Full Text] [Related]
13. [Invasive form of pulmonary aspergillosis in a patient with chronic lymphocytic leukemia successfully treated with amphotericin B].
Korzeniewska-Koseła M; Krakówka P; Halweg H; Szymczyk E
Pneumonol Pol; 1988 Aug; 56(8):366-71. PubMed ID: 3075740
[No Abstract] [Full Text] [Related]
14. Combination therapy in a model of pulmonary aspergillosis.
Schmitt HJ; Bernard EM; Edwards FF; Armstrong D
Mycoses; 1991; 34(7-8):281-5. PubMed ID: 1803227
[TBL] [Abstract][Full Text] [Related]
15. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients.
Conneally E; Cafferkey MT; Daly PA; Keane CT; McCann SR
Bone Marrow Transplant; 1990 Jun; 5(6):403-6. PubMed ID: 2196098
[TBL] [Abstract][Full Text] [Related]
16. [Fever and cavitary infiltrate in a renal transplant recipient].
Rocamora N; Tormo AM; Franco A; Alvarez Avellán L; Olivares J
Nefrologia; 2004; 24 Suppl 3():16-20. PubMed ID: 15219062
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
18. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases.
Dornbusch HJ; Urban CE; Pinter H; Ginter G; Fotter R; Becker H; Miorini T; Berghold C
Pediatr Hematol Oncol; 1995; 12(6):577-86. PubMed ID: 8589003
[TBL] [Abstract][Full Text] [Related]
19. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.
Wieland T; Liebold A; Jagiello M; Retzl G; Birnbaum DE
J Heart Lung Transplant; 2005 Jan; 24(1):102-4. PubMed ID: 15653389
[TBL] [Abstract][Full Text] [Related]
20. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
Patterson TF; Kirkpatrick WR; White M; Hiemenz JW; Wingard JR; Dupont B; Rinaldi MG; Stevens DA; Graybill JR
Medicine (Baltimore); 2000 Jul; 79(4):250-60. PubMed ID: 10941354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
